The objective of the NeuroMOtion project is to elucidate the common and/or different genetic and epigenetic architecture of NMOSD (Neuromyelitis Optica Spectrum Disorder) and MOGAD (MOG antibody-associated disease), in link with MS (multiple sclerosis). We aim to leverage the potential of genome-wide (GWAS) and epigenome-wide (EWAS) associations studies conducted in a unique clinical material to: 1) uncover key associations with NMOSD and MOGAD; 2) characterize NMOSD vs. MOGAD serological subgroups; 3) find common and unique genetic signatures between NMOSD, MOGAD and MS, for long considered subphenotypes of one disease. Moreover, we aim to address the functional impact of our findings using transcriptomic (RNAseq and scRNAseq) profiling and to integrate these molecular layers (genetic, epigenetic and transcriptomic) to discover crucial mechanisms underlying diseases etiology. We anticipate that our multi-omics approach will empower translational research in the field by discovering new biomarkers and facilitating a better understanding and management of neuroinflammatory diseases.